The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - eFFECTOR Therapeutics
Stock and Other Ownership Interests - eFFECTOR Therapeutics
A phase 1 dose escalation study of eFT508, an inhibitor of mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK-1) and MNK-2 in patients with advanced solid tumors.
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Research Funding - 3-V Biosciences; Abbvie; Aileron Therapeutics; ARMO BioSciences; AstraZeneca; Biothera; Celgene; Curegenix; Curis; DelMar Pharmaceuticals; eFFECTOR Therapeutics; EMD Serono; Fujifilm; Genmab; GlaxoSmithKline; Hutchison MediPharma; Incyte; Jounce Therapeutics; Kolltan Pharmaceuticals; Lilly; MedImmune; Millennium; Novartis; OncoMed; Precision Oncology; Regeneron; Strategia Therapeutics; Syndax; Taiho Pharmaceutical; Tesaro; Vegenics
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Millennium; Sarah Cannon Research Institute
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Clearlight Diagnostics; Genentech; Inflection Biosciences; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem; Zymeworks
 
Langdon L. Miller
Employment - Cleveland BioLabs; Sound Clinical Solutions, SP
Leadership - Cleveland BioLabs; Sound Clinical Solutions, SP
Stock and Other Ownership Interests - eFFECTOR Therapeutics
Consulting or Advisory Role - eFFECTOR Therapeutics
Expert Testimony - SRS Acquiom
 
Karen Morison
Stock and Other Ownership Interests - Amgen; Gilead Sciences; Pfizer
Consulting or Advisory Role - Auspex Pharmaceuticals; eFFECTOR Therapeutics; Mapp Biopharmaceutical; Teva
 
Debra Vallner
Employment - eFFECTOR Therapeutics
Leadership - eFFECTOR Therapeutics
Stock and Other Ownership Interests - eFFECTOR Therapeutics
 
Sam Sperry
Employment - eFFECTOR Therapeutics
Stock and Other Ownership Interests - eFFECTOR Therapeutics; IncellDx
 
Vikas Goel
Employment - eFFECTOR Therapeutics
Stock and Other Ownership Interests - eFFECTOR Therapeutics
Research Funding - eFFECTOR Therapeutics
Patents, Royalties, Other Intellectual Property - eFFECTOR Therapeutics
Travel, Accommodations, Expenses - eFFECTOR Therapeutics
 
Gary Gene Chiang
Employment - Abbvie; eFFECTOR Therapeutics
Stock and Other Ownership Interests - Abbvie
Research Funding - Abbvie; eFFECTOR Therapeutics
Patents, Royalties, Other Intellectual Property - AbbVie (Inst)
Travel, Accommodations, Expenses - Abbvie; eFFECTOR Therapeutics
 
Kevin Webster
No Relationships to Disclose
 
Jeremy Barton
Employment - eFFECTOR Therapeutics; Pfizer
Leadership - eFFECTOR Therapeutics
Stock and Other Ownership Interests - eFFECTOR Therapeutics; Pfizer
 
Manish R. Patel
Honoraria - Bristol-Myers Squibb; Exelis; Genentech; Gilead Sciences; Medivation
Consulting or Advisory Role - Guardant Health
Speakers' Bureau - Bristol-Myers Squibb; Exelis; Genentech; Gilead Sciences; Medivation